Serum Tumor Marker directed disease monitoring for Stage IV Breast Cancer
This trial studies how well using markers to prompt when scans should be ordered works in monitoring patients with hormone receptor positive Her2 negative breast cancer.
- Stage IV Breast Cancer
- Elevated Tumor Markers
- HER2/Neu Negative Breast Cancer
- Estrogen Receptor Positive
- Progesterone Receptor Positive
1 Primary · 3 Secondary · Reporting Duration: Up to 48 weeks after randomization
2 Treatment Groups
Arm I (usual care)
1 of 2
Arm II (serum tumor directed disease monitoring)
1 of 2
1320 Total Participants · 2 Treatment Groups
Primary Treatment: Serum Tumor Marker directed disease monitoring · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 21 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|Commonwealth Cancer Center-Corbin||100.0%|
What portion of applicants met pre-screening criteria?
Frequently Asked Questions
How many participants are currently enrolling in this clinical research?
"Indeed, the data accessible from clinicaltrials.gov indicates that this investigation is in search of participants at present. It was first listed on July 16th 2018 and has most recently been revised on March 8th 2022. A total of 1320 patients need to be enrolled across 100 unique sites." - Anonymous Online Contributor
How many medical facilities are currently conducting this research project?
"This research project is being conducted at 100 different medical centres, which include Sewell, Orland Park and Louisville. In order to better facilitate participant involvement, it is advisable that individuals select the closest clinic location in their vicinity." - Anonymous Online Contributor
Are there remaining vacancies in this medical research endeavor?
"As per information available on clinicaltrials.gov, this medical experiment is currently recruiting individuals. The trial was first posted on July 16th 2018 and underwent its most recent update in March of 2022." - Anonymous Online Contributor